Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative factors: a decline in revenue, gross margin, and operating margin, along with foreign exchange headwinds and regulatory risks. The Q&A section highlights concerns about tariffs and unclear management responses. Despite the accelerated share repurchase program, these issues outweigh the positives, leading to a negative sentiment. The market is likely to react negatively to the financial declines and uncertainties, resulting in a stock price drop between -2% and -8% over the next two weeks.
Revenue $700.7 million, down 5% year-over-year on a GAAP basis; decline of 3.8% on adjusted constant currency basis due to softness in orders in EMEA.
Adjusted Earnings Per Share (EPS) $2.91, a 9.3% decrease year-over-year; decrease reflects lower revenue, lower operating margins, foreign exchange impact, and a higher tax rate.
Adjusted Gross Margin 60.4%, a 70 basis point decrease year-over-year; decrease due to macroeconomic factors affecting labor and raw materials, and unfavorable product mix.
Adjusted Operating Margin 24.7%, a 190 basis point decline year-over-year; decline driven by lower gross margin, employee-related expenses, and investments to grow the business.
Net Interest Expense $16.6 million, a decrease from $21 million in the prior year; decrease reflects lower interest rates and lower debt outstanding.
Adjusted Tax Rate 14.5%, compared to 13.2% in the prior year; increase due to additional costs from European tax reforms.
Cash Flow from Operations $73.3 million, compared to $112.8 million in the prior year; decrease primarily due to operating results and unfavorable changes in working capital.
Cash and Cash Equivalents $317.5 million, down from $327.7 million at year-end 2024.
Net Leverage Approximately 1.8x at quarter end.
Accelerated Share Repurchase Program Completed on April 9, 2025, with over 2.2 million shares repurchased at an average price of $135.23.
New Product Launch: The AC3 range Intra-Aortic Balloon Pump has received 510(k) clearance from the FDA and will enter full market release in the U.S. in Q2 2025. The Ringer Perfusion Balloon Catheter IDE Study showed favorable preliminary results, supporting a premarket application for a coronary perforation indication. QuikClot Control+ received FDA clearance for expanded indications to include all grades of internal and external bleeding, potentially adding over $150 million to the serviceable market.
Market Expansion: The acquisition of BIOTRONIK Vascular Intervention business is on track to close by Q3 2025, enhancing Teleflex's portfolio in the cath lab and expanding its global presence. The Ringer PBC Study aims to support a coronary perforation indication, targeting a global market estimated at over $80 million.
Operational Efficiency: Adjusted gross margin was 60.4%, a 70 basis point decrease year-over-year, primarily due to macroeconomic factors and unfavorable product mix. Cash flow from operations decreased to $73.3 million, down from $112.8 million year-over-year, attributed to operating results and unfavorable changes in working capital.
Strategic Shift: Teleflex plans to separate into two independent publicly traded companies to enhance shareholder value and allow tailored strategic directions. Management is exploring options for the potential sale of NewCo in parallel with the proposed separation.
Revenue Decline: Teleflex reported a revenue decline of 5% year-over-year, attributed to softness in orders in EMEA and challenges in the UroLift office sites of service.
OEM Business Pressure: The OEM business experienced a 26.8% revenue decrease year-over-year due to the impact of lost customer contracts and inventory management.
China Procurement Impact: The company faced a 9.7% revenue decrease in Asia, primarily due to volume-based procurement in China, which is expected to improve sequentially.
Tariff Impact: Tariffs are projected to impact 2025 results by approximately $55 million, with significant portions related to China and Mexico, creating uncertainty in cost structures.
Gross Margin Decline: Adjusted gross margin decreased by 70 basis points year-over-year, primarily due to macroeconomic factors affecting labor and raw materials.
Operating Margin Pressure: Adjusted operating margin declined by 190 basis points year-over-year, driven by lower gross margins and increased employee-related expenses.
Foreign Exchange Headwinds: The company anticipates a negative impact from foreign exchange of $5 million, which could affect overall revenue growth.
Regulatory Approval Risks: The acquisition of BIOTRONIK's Vascular Intervention business is subject to customary closing conditions, including regulatory approvals, which may pose risks to the timeline.
Separation of Teleflex: On February 27, Teleflex announced the intention to separate into 2 independent publicly traded companies to enhance shareholder value, allowing each business to pursue tailored strategic directions.
Acquisition of BIOTRONIK Vascular Intervention: Teleflex is on track to close the acquisition of BIOTRONIK's Vascular Intervention business by the end of Q3 2025, which will enhance its portfolio and global presence in the cath lab.
FDA Clearances: Teleflex received FDA clearance for the AC3 range Intra-Aortic Balloon Pump and expanded indications for QuikClot Control+, targeting a serviceable addressable market of over $150 million.
2025 Revenue Growth Guidance: Teleflex expects adjusted constant currency revenue growth of 1% to 2% for 2025, with reported revenue growth now projected between $3.086 billion and $3.117 billion.
2025 Adjusted EPS Guidance: Adjusted earnings per share for 2025 is now expected to be in the range of $13.20 to $13.60, reflecting headwinds from tariffs.
Gross Margin Guidance: 2025 gross margin is expected to be in the range of 58.25% to 59%, with a significant portion of the reduction attributed to tariffs.
Operating Margin Guidance: Operating margins for 2025 are projected to be between 24.6% and 25%.
Tariff Impact: Teleflex anticipates a $55 million impact from tariffs in 2025, primarily associated with China and Mexico.
Accelerated Share Repurchase Program: Teleflex entered into a $300 million accelerated share repurchase program on February 28, 2025, which was completed on April 9, 2025. The company repurchased just over 2.2 million shares at an average price of $135.23 per share.
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
The earnings call reveals several negative indicators: declining unit and dollar volumes, reduced market share, and underperformance of past loan vintages. Although there is some positive news with the 2025 vintage exceeding expectations and share repurchases, the overall sentiment is dampened by intense competition, tariffs, and rising costs. The Q&A section highlights concerns about unclear management responses and potential negative economic returns, further contributing to a negative outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
